Firebrick Pharma Limited · ASX:FRE

Firebrick Pharma — Conference Presentation (October 2023)

22 slides from Firebrick Pharma's conference presentation, October 2023

  1. Slide 1: Nasal disinfection as a front-line defense in future pandemics

    Slide 1: Nasal disinfection as a front-line defense in future pandemics

    Nasal Nasal disinfection disinfection as as aa front-line front-line defense defense in in future future pandemics pandemics Professor Professor Peter Friedland Peter Friedland Garnett Garnett Passe Passe Rodney Rodney Williams Williams Chair Chair of Otolaryngology, of Otolaryngology, HeadHead & Ne

  2. Slide 2: Disclosures

    Slide 2: Disclosures

    Disclosures ● The following presentation is the view of the presenter and does not represent the views of the Australian Defence Force ● I was medical advisor and medical monitor for the two COVID-19 clinical trials described in this presentation, and I receive consultancy fees from the sponsor of t

  3. Slide 3: The case of COVID-19

    Slide 3: The case of COVID-19

    The case of COVID-19 ● SARS-CoV-2 is a respiratory virus » Enters primarily through the nose, where an initial infection is established » Likely through aspiration of the virus from the upper respiratory tract, the virus enters the lungs causing a more serious infection that in some cases is associa

  4. Slide 4: Published trials of povidone-iodine in COVID-19

    Slide 4: Published trials of povidone-iodine in COVID-19

    Paper Study type, location Covid Subjects Regimen Results Choudhury RCT N= 606 Combined regimen: 1% PVP-I gargle, nasal drops and eye PVP-I reduced (a) days to PCR-negative, and (b) rates of (2020) Malaysia 1:1 PVP-I or water drops, applied 4 hourly for 4 weeks hospitalisation and/or death Guenezan

  5. Slide 5: Rationale for nasal disinfection with povidone-iodine (PVP-I)

    Slide 5: Rationale for nasal disinfection with povidone-iodine (PVP-I)

    Rationale for nasal disinfection with povidone-iodine (PVP-I) Why sanitising the nasal passages makes sense as an extension of PPE and hand sanitising in at-risk environments 5 Firebrick Pharma

  6. Slide 6: Why povidone-iodine (PVP-I)?

    Slide 6: Why povidone-iodine (PVP-I)?

    Why povidone-iodine (PVP-I)? POVIDONE-IODINE ● PVP-I has been available and widely used for at least 6 decades molecular iodine (I2) solubilised in helical as an antiseptic, including nearly 40 years in Australia as a PVP polymer that acts as controlled-release reservoir popular gargle for sore thro

  7. Slide 7: Antiviral activity and spectrum

    Slide 7: Antiviral activity and spectrum

    Antiviral activity and spectrum ● Viruses classified as enveloped or non-enveloped (‘naked’) viruses ● PVP-I (at low concentration) inactivates both types » Damages viral envelope and capsid » Attacks nucleoproteins Coronaviruses Rhinovirus ● Enveloped viruses are acutely Influenza, RSV Adenovirus s

  8. Slide 8: PVP-I's unique chemistry: benefits and challenges

    Slide 8: PVP-I's unique chemistry: benefits and challenges

    PVP-I’s unique chemistry: benefits and challenges ● Adverse effects of PVP-I are related to concentration 0.5% PVP-I has greater antimicrobial » Ciliotoxicity at ≥2.5% and cytotoxicity at 5-10% potency than 5% PVP-I but lower » Risk of sensitivity and iodine absorption increase with PVP-I residual ‘

  9. Slide 9: Development of a PVP-I Nasal Spray

    Slide 9: Development of a PVP-I Nasal Spray

    Development of a PVP-I Nasal Spray ● Development started in 2012 by Melbourne-based Firebrick Pharma Ltd » Initial goal was for use as a treatment for the common cold » Hypothesis: reducing nasal viral load leads to a reduction in cold duration and/or severity » Formulation work completed over 2014-

  10. Slide 10: Nasodine Nasal Spray

    Slide 10: Nasodine Nasal Spray

    Nasodine® Nasal Spray ● After several years, a stable product and package was developed with a 2- year shelf-life at 30°C ● GMP manufacturing established in Melbourne and a complete CMC (chemistry, manufacturing, quality) package developed to support approval ● A dose of 3-4 sprays per nostril (tota

  11. Slide 11: Clinical experience

    Slide 11: Clinical experience

    Clinical experience ● 2018: Phase I study in healthy adult volunteers (N=10) » Conducted in Adelaide » 20 doses applied 4 times daily for 5 days, each dose 4 sprays per nostril (1.12 mL) » Iodine uptake occurred, but not clinically significant and below recommended daily upper limit for iodine in th

  12. Slide 12: Clinical experience

    Slide 12: Clinical experience

    Clinical experience ● 2019: Phase III trial in adults with common cold (N=260): » Conducted at sites in Adelaide and Brisbane » 20 doses applied 4 times daily for 5 days, dose reduced to 3 sprays per nostril (0.84 mL) » Placebo was saline nasal spray; cold symptom impact measured using WURSS-21 » Na

  13. Slide 13: Clinical experience in COVID-19

    Slide 13: Clinical experience in COVID-19

    Clinical experience in COVID-19 Nasodine’s potential role as a nasal disinfectant 13 Firebrick Pharma

  14. Slide 14: Virucidal pilot study of Nasodine in people with COVID-19

    Slide 14: Virucidal pilot study of Nasodine in people with COVID-19

    Virucidal pilot study of Nasodine® (povidone-iodine 0.5%) nasal spray in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus Open-label human trial in South Africa to assess the impact of a single dose of Nasodine® on shedding of SARS-CoV-2 over one hour post-dose in patients with

  15. Slide 15: Study overview

    Slide 15: Study overview

    Study overview ● Objective » To assess impact of a single dose of Nasodine on viral shedding of SARS-CoV-2 over 1 hour post-dose ● Subjects and methods » Enrolled 23 adults with symptoms of COVID-19; baseline nasal swabs collected for PCR and viral culture » All received a single dose (1.12 ml) of N

  16. Slide 16: Reduction of nasal shedding of SARS-CoV-2 in COVID-19 positive patients

    Slide 16: Reduction of nasal shedding of SARS-CoV-2 in COVID-19 positive patients

    Reduction of nasal shedding of SARS-CoV-2 in COVID-19 positive patients by the use of Nasodine® (povidone-iodine 0.5%) Nasal Spray Randomised, placebo-controlled, Phase 2 trial in subjects with COVID-19 symptoms, to assess the impact of 20 doses of Nasodine on viral shedding of SARS-CoV-2 over a 5-d

  17. Slide 17: Study overview

    Slide 17: Study overview

    Study overview ITT (intent-to-treat) Recruitment: • 39 Adults (18+) ITT = 39 Primary endpoint • RAT-positive for COVID ITTi = 23 • COVID symptoms <3 days = Reduction in viral load (log10 TCID50) Days 2-4 • Safety/other criteria versus placebo nasal spray (water), based on mid-turbinate nasal swabs R

  18. Slide 18: Results: Primary endpoint and clearance by day

    Slide 18: Results: Primary endpoint and clearance by day

    Results: Primary endpoint and clearance by day Nasal Viral Load, Nasodine Vs Placebo Viral Clearance by Day 100% 100% 90% 90% Primary endpoint: Percent of Subjects TCID50<LOD (0.75 log) LSM (AUC) of Log10TCID50 titres Reduction from Baseline (Mean D1, D2) 80% (viral load) over Days 2-4: 80% Treatmen

  19. Slide 19: Trial results: Symptoms and days to RAT-negative

    Slide 19: Trial results: Symptoms and days to RAT-negative

    Trial results: Symptoms and days to RAT-negative Symptom Scores RAT Positive Rates 100% 24 90% 6% reduction in AUC of 22 symptoms over days 2-5 80% % of ITT Subjects RAT-positive Placebo Placebo 70% 20 Nasodine Nasodine Symptom Score* 60% 18 50% 16 40% 30% 14 20% 12 10% 10 0% D1 D2 D3 D4 D5 D1 D2 D3

  20. Slide 20: Key conclusions

    Slide 20: Key conclusions

    Key conclusions ● Primary endpoint of reduction in shedding was met (p=0.028) ● Nasodine treatment resulted in 100% reduction in viral load by day 4, after completion of the treatment regimen on day 3 ● 100% of Nasodine-treated subjects had cleared the virus by day 4 based on mid- turbinate nasal sw

  21. Slide 21: Implications

    Slide 21: Implications

    Implications ● For COVID-19, the period of active shedding after symptom onset is 6-9 days (source: NIH); in this trial, subjects had symptoms for up to 3 days prior to enrolment, so that in most cases, there was already a natural decline in viral load occurring at start of treatment. ● It is challe

  22. Slide 22: Nasal Disinfection as a front-line defense in future pandemics

    Slide 22: Nasal Disinfection as a front-line defense in future pandemics

    Nasal Disinfection as a front-line defense in future pandemics 22

Source: Internet Archive copy of firebrickpharma.com

More decks from Firebrick Pharma Limited

All 9 Firebrick Pharma decks